搜尋
Abcellera Biologics Inc
ABCL添加自選
7.600USD
-0.250-3.18%
收盤 07/01, 16:00（美東）報價延遲15分鐘
2.31B總市值
虧損本益比TTM
關於 Abcellera Biologics Inc 公司
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
Abcellera Biologics Inc簡介
公司代碼ABCL
公司名稱Abcellera Biologics Inc
上市日期Dec 11, 2020
CEOHansen (Carl L.G)
員工數量596
證券類型Ordinary Share
年結日Dec 11
公司地址150 W 4Th Avenue
城市VANCOUVER
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Canada
郵編V5Y 1G6
電話16045599005
網址https://www.abcellera.com/
公司代碼ABCL
上市日期Dec 11, 2020
CEOHansen (Carl L.G)
Abcellera Biologics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
576.56K
+43.36%
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Michael R. Hayden
Dr. Michael R. Hayden
Lead Independent Director
Lead Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Dr. Sarah B. Noonberg, M.D., Ph.D.
Dr. Sarah B. Noonberg, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Stephen Quake
Mr. Stephen Quake
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
576.56K
+43.36%
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Michael R. Hayden
Dr. Michael R. Hayden
Lead Independent Director
Lead Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
常見問題
Abcellera Biologics Inc的前五大股東是誰？
Abcellera Biologics Inc的前五大股東如下：Dr. Veronique Lecault, Ph.D.
有多少機構持有Abcellera Biologics Inc(ABCL)的股份？
截至2026Q1，共有323家機構持有Abcellera Biologics Inc的股份，合計持有的股份價值約為131.69M，占公司總股份的43.14% 。與2025Q4相比，機構持股有所增加，增幅為-19217264.00。
哪個業務部門對Abcellera Biologics Inc的收入貢獻最大？
在2026Q1，Licensing revenue業務部門對Abcellera Biologics Inc的收入貢獻最大，創收46.92M，占總收入的62.45% 。